Olympus Reports Record FY2025 Medical Business Revenue of ¥996.8 Billion, Plans Segment Reorganization

Olympus Corporation reported strong financial results for the fiscal year ended March 31, 2025, with medical business revenue rising to a record ¥996.8 billion, up 7.9% from the prior year. Operating profit from the medical segment more than doubled to ¥202.9 billion, supported by solid growth in North America and Europe, while adjusted operating margin climbed to 22.9%.

Key drivers included strength in the Endoscopic Solutions Division (ESD), now set to be reorganized as the Gastrointestinal Solutions Division (GIS), and the Therapeutic Solutions Division (TSD), which will transition to the Surgical & Interventional Solutions Division (SIS) in FY2026.

Olympus also reported an increase in R\&D spending to ¥103.9 billion and generated free cash flow of ¥125 billion. The company ended the fiscal year with ¥1.43 trillion in total assets and an equity ratio of 52.5%.

The reorganization aims to better align operations with growth priorities and will take effect in the fiscal year ending March 2026.